Proc\ue9d\ue9 pour fixer d'une fa\ue7on stable del antig\ue8nes et des allerg\ue8nes sur des supports solides, et supports destin\ue9s \ue0 cet usage

a. Proc\ue9d\ue9 pour fixer d'une fa\ue7on stable del antig\ue8nes et des allerg\ue8nes sur des supports solides, an partuculier sur du polystyr\ue8ne. b. Caract\ue9ris\ue9 en ce qu'il comprend les phases suivantes: faire r\ue9agir un ald\ue9hyde polyfunctionnel avec le phase solide du support, eliminer l'exc\ue8s d'ald\ue9hyde par lavage, faire incuber la phase solide aimsi trait\ue9e avec les antig\ue8nes ou les allerg\ue8nes, et finalement stabiliser la liaison entre l'ald\ue9hyde et les antig\ue9nes ou les allerg\ue9nes par un traitement avec des substances r\ue9duisant la liaison ald-imin\ue9\ue8, c. Support solide utilisable pour d\ue9celer les amticorps des classes IgE, IgG, IgA ou IgM, sp\ue9cifiques pour des antig\ue9nes ou des allerg\ue9nes, soit aux fins de diagnostiquer una maladie allergique ou infectieuse, soit pour v\ue9erifier un \ue9tat d'immunit\ue9

Allergeni modificati chimicamente e procedimento per la loro preparazione

Metodo per legare in modo stabile antigeni ed allergeni ad un supporto di polistirene consistenye nel far reagire un aldeide polifunzionale con la fase solida del polistirene; nel lavare detta fase solida per allontanare l'aldeide in eccesso; nell'incubare la fase solida cos\uec trattata con gli antigeni o gli allergeni, e nello stabilizzare il legame aldeide-antigeni o allergeni con sodio boro idruro o sodio ciano boroidruro

The allergic march in pollinosis: Natural history and therapeutic implications - Results of a long-term parallel controlled observational study

Background: That specific immunotherapy ( SIT) can slow the march of allergy has been confirmed in controlled clinical trials. However, an assessment of its effects in everyday life, in a large cohort of patients, might provide further useful information. Methods: This observational study comprised 3,643 patients allergic to pollens; 1,620 with pure allergic rhinitis or rhinitis and intermittent or mild-persistent bronchial asthma, responding poorly to standard pharmacological therapy (SPT), were treated for 3 years with SPT alone ( pure rhinitis, n = 890), or combined with continuous SIT ( rhinitis and asthma, n = 730). Symptom/drug scores were recorded, respiratory function and skin tests were done, and methacholine challenge was scheduled at the beginning and end of the study. A series of 2,023 patients with pure rhinitis, responsive to SPT, were asked to 'self-medicate' as needed, serving as a control group to check the incidence of asthma. Results: The incidence of rhinitis-asthma comorbidity was highest in the self-medication group (50.8%). Persistent rhinitis was associated with asthma more often than the intermittent form, regardless of the severity of the symptoms that led to progression to asthma in patients with intermittent rhinitis. Treatment with SIT combined with SPT always slowed the allergic march which, however, was not influenced by drugs alone. Conclusions: In routine clinical practice, SIT is effective in preventing the allergic march. Patients with persistent rhinitis, who are at greatest risk of progression to asthma, appear to be the most logical candidates. Copyright (C) 2004 S. Karger AG, Basel